Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2T Strategy with Secukinumab in Active axSpA
NCT03906136Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of secukinumab in axial spondyloarthritis (axSpA), sponsored by Novartis. Started Jun 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03906136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906136.